نتایج جستجو برای: cd19

تعداد نتایج: 4797  

Journal: :Blood 1998
M N Dworzak G Fritsch G Fröschl D Printz H Gadner

Terminal deoxynucleotidyl transferase (TdT)-positive cells in human bone marrow (BM) are a phenotypically inhomogeneous population of precursor cells. In their majority, these TdT+ cells are unambiguously committed to the B lineage, as evidenced by CD19 expression. However, TdT+ precursors that lack CD19 also exist and these may encompass a differentiation potential for the B as well as for oth...

Journal: :Blood 1993
H Harada M M Kawano N Huang Y Harada K Iwato O Tanabe H Tanaka A Sakai H Asaoku A Kuramoto

We have recently shown that two-color analysis with fluorescein isothiocyanate (FITC)-anti-CD38 antibody could clearly distinguish myeloma cells (plasma cells) from other hematopoietic cells in the bone marrow. Myeloma cells (plasma cells) alone were located at CD38strong positive (++) fractions. To further distinguish normal plasma cells from mature myeloma cells phenotypically, we examined im...

Journal: :Haematologica 2006
Xu Zheng Saeid Abroun Ken-ichiro Otsuyama Hideki Asaoku Michio M Kawano

BACKGROUND AND OBJECTIVES An increased level of serum M-protein IgG may affect the growth or survival of myeloma cells through the Fcgamma inverted exclamation mark receptor (FcgammaR) in human myelomas. We examined the expression of FcgammaR (CD32, CD16 and CD64) and compared the effect of anti-CD32 antibody on the viability of myeloma cells to that on the viability of normal plasma cells. D...

2013
Adrienne H Long Rimas J Orentas Crystal L Mackall

Chimeric antigen receptors (CARs) provide a promising new approach for generating T cell populations for the adoptive immunotherapy of cancer. CAR T cell (CART) therapies demonstrate activity against leukemias in preclinical and clinical studies, but CART targeting solid tumors have been less impressive. We hypothesized that the observed differences could be due to a more hostile microenvironme...

Journal: :Cancer discovery 2015
Elena Sotillo David M Barrett Kathryn L Black Asen Bagashev Derek Oldridge Glendon Wu Robyn Sussman Claudia Lanauze Marco Ruella Matthew R Gazzara Nicole M Martinez Colleen T Harrington Elaine Y Chung Jessica Perazzelli Ted J Hofmann Shannon L Maude Pichai Raman Alejandro Barrera Saar Gill Simon F Lacey Jan J Melenhorst David Allman Elad Jacoby Terry Fry Crystal Mackall Yoseph Barash Kristen W Lynch John M Maris Stephan A Grupp Andrei Thomas-Tikhonenko

UNLABELLED The CD19 antigen, expressed on most B-cell acute lymphoblastic leukemias (B-ALL), can be targeted with chimeric antigen receptor-armed T cells (CART-19), but relapses with epitope loss occur in 10% to 20% of pediatric responders. We detected hemizygous deletions spanning the CD19 locus and de novo frameshift and missense mutations in exon 2 of CD19 in some relapse samples. However, w...

2012
Kemeng Wang Guoqing Wei Delong Liu

The human CD19 antigen is a 95 kd transmembrane glycoprotein belonging to the immunoglobulin superfamily. CD19 is classified as a type I transmembrane protein, with a single transmembrane domain, a cytoplasmic C-terminus, and extracellular N-terminus. CD19 is a biomarker for normal and neoplastic B cells, as well as follicular dendritic cells. CD19 is critically involved in establishing intrins...

Journal: :The Journal of clinical investigation 2016
Marco Ruella David M Barrett Saad S Kenderian Olga Shestova Ted J Hofmann Jessica Perazzelli Michael Klichinsky Vania Aikawa Farzana Nazimuddin Miroslaw Kozlowski John Scholler Simon F Lacey Jan J Melenhorst Jennifer J D Morrissette David A Christian Christopher A Hunter Michael Kalos David L Porter Carl H June Stephan A Grupp Saar Gill

Potent CD19-directed immunotherapies, such as chimeric antigen receptor T cells (CART) and blinatumomab, have drastically changed the outcome of patients with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). However, CD19-negative relapses have emerged as a major problem that is observed in approximately 30% of treated patients. Developing approaches to preventing and treating a...

Journal: :The Keio journal of medicine 2000
T F Tedder S Sato J C Poe M Fujimoto

The fate of B lymphocytes is dependent on intrinsic and B cell antigen receptor (BCR)-induced signals. These signals are modified and interpreted by other cell-surface molecules such as CD19 and CD22 that govern mature B cell activation. This review assesses our current understanding of how CD19 and CD22 regulate B lymphocyte signaling and how alterations in these response-regulators contribute...

2017
Yu Zhang Gaizhi Zhu He Xiao Xiaoling Liu Gencheng Han Guojiang Chen Chunmei Hou Beifen Shen Yan Li Ning Ma Renxi Wang

As the first line of defence, marginal zone (MZ) B cells play principal roles in clearing blood-borne pathogens during infection and are over-primed in autoimmune diseases. However, the basic mechanisms underlying MZ B-cell development are still unclear. We found here that CD19 deficiency blocked the differentiation of marginal zone precursors (MZP) to MZ B cells, whereas CD19 expression in CD1...

Journal: :The Journal of Experimental Medicine 1993
A K Matsumoto D R Martin R H Carter L B Klickstein J M Ahearn D T Fearon

The CD21/CD19/TAPA-1 complex of B lymphocytes amplifies signal transduction through membrane immunoglobulin (mIg), recruits phosphatidylinositol 3-kinase (PI3-kinase), and induces homotypic cellular aggregation. The complex is unique among known membrane protein complexes of the immune system because its components represent different protein families, and can be expressed individually. By cons...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید